Axsome Therapeutics Endures $130M Insider Sell‑off, CEO Dumps $76M in 12‑Month Span

Over the last twelve months Axsome Therapeutics recorded three insider purchases totaling $200,466 and 44 insider sales worth $129,772,380, yielding a buy‑to‑sell ratio of 0.00x—well below the 0.2x threshold that flags heavy selling. The total transaction value of $129.97 million exceeds the $1 million materiality benchmark, confirming that the activity is significant enough to merit close scrutiny.

The most striking element is the concentration of sales among senior executives. CEO Tabuteau Herriot executed five separate trades between November 2025 and February 2026, disposing of 302,529 shares for $45.5 million. In aggregate, the CEO’s eight sales total $76,141,116, representing 58% of all insider sell value. The COO contributed seven sales worth $19.1 million, while the CFO’s lone sale amounted to $2.26 million. Directors collectively bought a modest $200,466 and sold $25.86 million, a net sell of $25.66 million.

The timing of the sales aligns with a series of high‑volume months. From May 2024 through April 2026, every month with recorded activity posted only sales, with peak sell‑off in November 2025 ($21.8 million) and January 2026 ($27.5 million). The absence of any buying activity from the C‑suite during this period eliminates the possibility of offsetting purchases that sometimes accompany compensation‑related sales.

Market context provides a partial backdrop. Axsome’s share price sits at $193.29, up 3.94% on the day and 1.8% year‑to‑date, while the RSI of 71 suggests the stock is approaching overbought territory. The stock trades near the top of its 52‑week range (94%) and carries a market cap of $9.9 billion. In April 2026 the company announced the acquisition of the selective PDE10A inhibitor balipodect, a move intended to broaden its CNS pipeline. While such an acquisition can require cash, the scale of insider selling—especially by the CEO—exceeds what would be expected from routine diversification or tax planning. Historically, C‑suite sales that exceed $10 million in a single year are rare and often interpreted as a lack of confidence in upcoming catalysts.

Given the magnitude of the sell‑off, the concentration among top executives, and the sub‑threshold buy‑to‑sell ratio, the insider activity leans heavily toward a bearish signal. Investors should weigh this evidence alongside the company’s recent acquisition and its current valuation metrics before making allocation decisions.